Maximizing Therapeutic Impact with CD20- and CD19-Targeted T Cell Engagers in Autoimmune Disease
Time: 9:30 am
day: Day Two
Details:
- Evaluating B cell expression in CD20 vs CD19 to weigh the risks and benefits
- Engineering Bispecific antibodies by selecting the most effective formats for autoimmune disease applications
- Tuning the potency and half-life of Bispecific antibodies to optimize their therapeutic index
